Hormonal
Activation of the NR4A nuclear receptor subgroup (specifically Nur77 and Nor-1) mediates metabolic homeostasis in skeletal muscle and liver, where its loss leads to insulin resistance, impaired glucose clearance, and lipid accumulation, while its activation enhances glucose transport and fatty acid oxidation.
This research suggests that physical activity and certain dietary components act as signals to activate NR4A receptors (like Nur77 and Nor-1) in your muscles and liver. When these receptors are active, they help your cells take up glucose and burn fatty acids more effectively. Conversely, inactivity or high-fat diets may suppress these receptors, contributing to insulin resistance. While no specific 'dose' of exercise is prescribed here, the mechanism implies that regular metabolic stress (exercise) and nutrient sensing (diet) are required to maintain this protective signaling pathway.
In vivo, Nur77 appears to regulate the expression of metabolic genes specifically involved in glucose transport, insulin signaling (such as Glut4), glycolysis, and glycogenolysis... Phenotypically, Nur77 null mice exhibited... insulin resistance in skeletal muscle, and slower blood glucose clearance.
Why this rating
The paper is a minireview summarizing multiple in vitro and in vivo studies (knockout mice, siRNA, adenoviral overexpression), but lacks large-scale human clinical trial data.
Source
Minireview: Nuclear Hormone Receptor 4A Signaling: Implications for Metabolic Disease
Michael A. Pearen et al. · Molecular Endocrinology · 2010
DOI 10.1210/me.2010-0015
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →